Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Lu, Xiao ^a   Guo, Xiaomei ^a   Karathanasis, Sotirios K ^d,f   Zimmerman, Karen M ^d   Onyia, Jude E ^d   Peterson, Richard G ^e   Kassab, Ghassan S ^a,b,c  

^a Indiana University Purdue University Indianapolis   (United States)

^b INDIANA UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e PreClinOmics   (United States)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; CALCIUM; ELASTASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE B; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; NOS3 PROTEIN, RAT; PANCREATIC ELASTASE; TRIACYLGLYCEROL; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL REGENERATION; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL FUNCTION; EX VIVO STUDY; FEMORAL ARTERY; MYOGRAPHY; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; TREATMENT RESPONSE; VASOCONSTRICTION; VASODILATATION; YOUNG MODULUS; ZUCKER DIABETIC FATTY RAT; ANIMAL; BLOOD; BLOOD PRESSURE; BODY WEIGHT; DIABETIC ANGIOPATHY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; TIME; VASCULAR ENDOTHELIUM; ZUCKER RAT;

ADIPOSITY; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMORAL ARTERY; HYPOGLYCEMIC AGENTS; MATRIX METALLOPROTEINASE 9; MYOGRAPHY; NITRIC OXIDE SYNTHASE TYPE III; PANCREATIC ELASTASE; RATS; RATS, ZUCKER; RECEPTORS, ADRENERGIC, ALPHA; THIAZOLIDINEDIONES; TIME FACTORS; TRIGLYCERIDES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 77952295410     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-19     Document Type: Article

References (35)

1. Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: An overview. Am J Hypertens 2001, 14:47-86.
2. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992, 19(5):403-418.
3. Kaur J, Singh P, Sowers JR. Diabetes and cardiovascular diseases. Am J Ther 2002, 9(6):510-515. 10.1097/00045391-200211000-00009, 12424509.
4. Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I, Schoenhagen P, Nissen SE. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 2008, 52(4):255-262. 10.1016/j.jacc.2008.03.051, 18634979.
5. Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Lund DD, Adebara ET, Yorek MA. Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse. Diabetes Obes Metab 2008, 10(1):64-74.
6. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001, 37(4):1053.
7. Sowers JR. Treatment of hypertension in patients with diabetes. Arch Intern Med 2004, 164(17):1850-1857. 10.1001/archinte.164.17.1850, 15451759.
8. Chinen I, Shimabukuro M, Yamakawa K, Higa N, Matsuzaki T, Noguchi K, Ueda S, Sakanashi M, Takasu N. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology 2007, 148(1):160-165. 10.1210/en.2006-1132, 17023526.
9. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104(22):2673-2678. 10.1161/hc4601.099485, 11723017.
10. Thuillez C, Richard V. Targeting endothelial dysfunction in hypertensive subjects. J Hum Hypertens 2005, 19(Suppl 1):S21-25. 10.1038/sj.jhh.1001889, 16075029.
11. Hayden MR, Sowers JR, Tyagi SC. The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc Diabetol 2005, 4(1):9. 10.1186/1475-2840-4-9, 1175853, 15985157.
12. Camp TM, Tyagi SC, Senior RM, Hayden MR, Tyagi SC. Gelatinase B (MMP-9) an apoptotic factor in diabetic transgenic mice. Diabetologia 2003, 46:1438-1446. 10.1007/s00125-003-1200-y, 12928773.
13. Liu SQ, Fung YC. Changes in the rheological properties of blood vessel tissue remodeling in the course of development of diabetes. Biorheology 1992, 29(5-6):443-457.
14. Liu SQ, Fung YC. Influence of STZ-induced diabetes on zero-stress states of rat pulmonary and systemic arteries. Diabetes 1992, 41(2):136-146. 10.2337/diabetes.41.2.136, 1733801.
15. Reddy HK, Koshy SK, Foerst J, Sturek M. Remodeling of coronary arteries in diabetic patients-an intravascular ultrasound study. Echocardiography 2004, 21(2):139-144. 10.1111/j.0742-2822.2004.03014.x, 14961792.
16. Reddy HK, Koshy SK, Wasson S, Quan EE, Pagni S, Roberts AM, Joshua IG, Tyagi SC. Adaptive-outward and maladaptive-inward arterial remodeling measured by intravascular ultrasound in hyperhomocysteinemia and diabetes. J Cardiovasc Pharmacol Ther 2006, 11(1):65-76. 10.1177/107424840601100106, 16703221.
17. Zhao J, Lu X, Zhuang F, Gregersen H. Biomechanical and morphometric properties of the arterial wall referenced to the zero-stress state in experimental diabetes. Biorheology 2000, 37(5-6):385-400.
18. Martinez-Lemus LA, Wu X, Wilson E, Hill MA, Davis GE, Davis MJ, Meininger GA. Integrins as unique receptors for vascular control. J Vasc Res 2003, 40(3):211-233. 10.1159/000071886, 12902635.
19. Peterson RG, Shaw WN, Neel MA, Little LA, Eichberg J. Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. Ilar News 1990, 32:16-19.
20. Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, Ohlstein EH, Jucker BM. Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005, 54(2):554-562. 10.2337/diabetes.54.2.554, 15677515.
21. Mittermayer F, Schaller G, Pleiner J, Krzyzanowska K, Kapiotis S, Roden M, Wolzt M. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. J Clin Endocrinol Metab 2007, 92(7):2574-80. 10.1210/jc.2006-2130, 17473072.
22. Laughlin MH, Turk JR, Schrage WG, Woodman CR, Price EM. Influence of coronary artery diameter on eNOS protein content. Am J Physiol Heart Circ Physiol 2003, 284(4):H1307-1312.
23. Lu X, Kassab GS. Vasoactivity of blood vessels using a novel isovolumic myograph. Ann Biomed Eng 2007, 35(3):356-66. 10.1007/s10439-006-9243-0, 17221307.
24. Stepp DW, Frisbee JC. Augmented adrenergic vasoconstriction in hypertensive diabetic obese Zucker rats. Am J Physiol Heart Circ Physiol 2002, 282(3):H816-820.
25. Faber JE, Szymeczek CL, Cotecchia S, Thomas SA, Tanoue A, Tsujimoto G, Zhang H. Alpha1-adrenoceptor-dependent vascular hypertrophy and remodeling in murine hypoxic pulmonary hypertension. Am J Physiol Heart Circ Physiol 2007, 292(5):H2316-2323. 10.1152/ajpheart.00792.2006, 17220188.
26. Struijker-Boudier HA, Smits JF, De Mey JG. Pharmacology of cardiac and vascular remodeling. Annu Rev Pharmacol Toxicol 1995, 35:509-539. 10.1146/annurev.pa.35.040195.002453, 7598505.
27. Teeters JC, Erami C, Zhang H, Faber JE. Systemic alpha 1A-adrenoceptor antagonist inhibits neointimal growth after balloon injury of rat carotid artery. Am J Physiol Heart Circ Physiol 2003, 284(1):H385-392.
28. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004, 27(2):484-490. 10.2337/diacare.27.2.484, 14747233.
29. Vinik AI, Stansberry KB, Barlow PM. Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus. J Diabetes Complications 2003, 17(5):279-285. 10.1016/S1056-8727(03)00006-0, 12954157.
30. Johns DG, Ao Z, Eybye M, Olzinski A, Costell M, Gruver S, Smith SA, Douglas SA, Macphee CH. Rosiglitazone protects against ischemia/reperfusion-induced leukocyte adhesion in the zucker diabetic fatty rat. J Pharmacol Exp Ther 2005, 315(3):1020-1027. 10.1124/jpet.105.090993, 16123307.
31. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004, 89(6):2728-35. 10.1210/jc.2003-032103, 15181049.
32. Naoumova RP, Kindler H, Leccisotti L, Mongillo M, Khan MT, Neuwirth C, Seed M, Holvoet P, Betteridge J, Camici PG. Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2007, 50(21):2051-2058. 10.1016/j.jacc.2007.07.070, 18021872.
33. Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, Ma XL, Batinic-Haberle I, Willette RN, Ohlstein EH, Yue TL. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 2003, 108(22):2805-2811. 10.1161/01.CIR.0000097003.49585.5E, 14610009.
34. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809. 10.1038/362801a0, 8479518.
35. Rozanski A, Qureshi E, Bauman M, Reed G, Pillar G, Diamond GA. Peripheral Arterial Responses to Treadmill Exercise Among Health Subjects and Atherosclerotic Patients. Circulation 2001, 103(16):2084-2089.